Pegaptanib
- Generic Name
- Pegaptanib
- Drug Type
- Biotech
- CAS Number
- 222716-86-1
- Unique Ingredient Identifier
- 3HP012Q0FH
- Background
Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.
Pegaptanib was granted FDA approval on 17 September 2004.
- Indication
For the treatment of neovascular (wet) age-related macular degeneration.
- Associated Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- Greater Houston Retina Research
- Registration Number
- NCT01589718
- Locations
- 🇺🇸
Retina Consultants of Houston, Houston, Texas, United States
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
- Conditions
- Age-Related Macular DegenerationRetinal Vein OcclusionDiabetic Macular Edema
- Interventions
- First Posted Date
- 2012-04-09
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 131
- Registration Number
- NCT01573572
- Locations
- 🇺🇸
Wolfe Eye Clinic, Marshalltown, Iowa, United States
🇺🇸Valley Retina Institute, Harlingen, Texas, United States
🇺🇸Marietta Eye Clinic, Murrieta, California, United States
Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- Valley Retina Institute
- Target Recruit Count
- 72
- Registration Number
- NCT01486238
- Locations
- 🇺🇸
Valley Retina Institute,PA, McAllen, Texas, United States
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.
- Conditions
- High Risk Proliferative Diabetic RetinopathyDiabetes Mellitus Type IDiabetes Mellitus Type II
- Interventions
- Procedure: Panretinal Photocoagulation (PRP)
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2015-03-19
- Lead Sponsor
- Association for Innovation and Biomedical Research on Light and Image
- Target Recruit Count
- 22
- Registration Number
- NCT01281098
- Locations
- 🇵🇹
Center for Clinical Trials - Aibili, Coimbra, Portugal
Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
- Conditions
- Macular DegenerationAge-related Macular DegenerationNeovascular Macular Degeneration
- Interventions
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2011-01-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1001
- Registration Number
- NCT01245387
Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia
- Conditions
- Myopic Choroidal Neovascular Membrane
- Interventions
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- L.V. Prasad Eye Institute
- Registration Number
- NCT01218230
- Locations
- 🇮🇳
LV Prasad Eye Institute, Hyderabad, AP, India
Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema
- Conditions
- Anti- VGF InhibitorDiabetic Macular EdemaDiabetic Retinopathy
- Interventions
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT01189461
- Locations
- 🇪🇸
Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain
🇸🇪Ogonkliniken, Centrallasarettet, Vasteras, Sweden
🇬🇧Kings College Hospital, London, United Kingdom
A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema
- Conditions
- Macular EdemaDiabetic MellitusRetinal Disease
- Interventions
- Other: sham injection
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2013-08-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 243
- Registration Number
- NCT01100307
- Locations
- 🇯🇵
Kohnan Hospital, Kobe, Hyogo, Japan
🇯🇵Nihon University Surugadai Hospital, Chiyoda-ku, Tokyo, Japan
🇯🇵Shiga University of Medical Science Hospital, Otsu, Shiga, Japan
Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT00858208
- Locations
- 🇬🇷
Pfizer Investigational Site, Xanthi, Greece
Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3538
- Registration Number
- NCT00845273
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.